AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:ZGNXZogenix Stock Price, Forecast & News

$29.19
+0.12 (+0.41 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$28.59
Now: $29.19
$29.98
50-Day Range
$25.47
MA: $28.96
$32.04
52-Week Range
$16.65
Now: $29.19
$57.22
Volume829,600 shs
Average Volume1.15 million shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Read More
Zogenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share

Profitability

Net Income$-419,500,000.00
Net Margins-8,374.54%

Miscellaneous

Employees90
Market Cap$1.62 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

How has Zogenix's stock been impacted by COVID-19 (Coronavirus)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX stock has increased by 28.6% and is now trading at $29.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zogenix?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zogenix.

When is Zogenix's next earnings date?

Zogenix is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Zogenix.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($1.08) by $0.54. The business had revenue of $1.25 million for the quarter, compared to the consensus estimate of $0.38 million. Zogenix had a negative net margin of 8,374.54% and a negative return on equity of 47.19%. Zogenix's revenue for the quarter was up 124800.0% on a year-over-year basis. During the same period last year, the business earned ($0.83) earnings per share. View Zogenix's earnings history.

What price target have analysts set for ZGNX?

11 equities research analysts have issued twelve-month target prices for Zogenix's shares. Their forecasts range from $27.00 to $78.00. On average, they anticipate Zogenix's share price to reach $56.80 in the next year. This suggests a possible upside of 94.6% from the stock's current price. View analysts' price targets for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (5/10/2020)
  • 2. Northland Securities analysts commented, "We note that 1504 demonstrated 63% and 54% reductions in mean monthly convulsive seizure frequency, versus comparator arms that excluded or included stiripentol therapy, respectively. FINTEPLA was also shown to significantly extend seizure free intervals to ~1 month, with an exceptionally high response rate >70%." (7/8/2019)

Has Zogenix been receiving favorable news coverage?

Press coverage about ZGNX stock has been trending negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zogenix earned a coverage optimism score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Zogenix.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $29.19.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.62 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 90 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.